Last Updated on Wednesday, 16 March, 2022 at 12:46 pm by Andre Camilleri
Malta-based pharmaceutical firm Pharmacare Premium Ltd is launching generic Sorafenib, a product used for the treatment of kidney and liver cancers, certain types of leukaemia and advanced thyroid cancer.
Sorafenib was developed at the company’s Hal Far facility in partnership with Greece’s Genepharm and will launch as soon as the patent for the original treatment, called Nexavar, expires in the target countries. More than 20 partners will now begin marketing and selling the product in at least 30 countries from Thailand to Mexico and from Canada to South Africa.
Hani Sarraf, Business Development Director of Pharmacare Premium Ltd, said: “The launch of Sorafenib, our generic version of Nexavar, is a very significant moment for Pharmacare Premium which highlights the quality of our research, development, and manufacturing capabilities. It is also a contribution to the global battle against several types of cancer, making treatments considerably cheaper and more accessible for patients across the globe.”
More information on Pharmacare Premium is available at https://pharmacarepremium.com/
